Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'
Key Takeaways Novo Nordisk shares rose Wednesday on the company's home market in Denmark and in the U.S. after UBS analysts ...
PulteGroup upgraded to Buy at UBS; MTH named top homebuilder pick
UBS Securities on Wednesday upgraded PulteGroup (NYSE:PHM) stock to Buy from Neutral, highlighting promising margins, while ...
UBS upgrades Bank of America to Buy and boosts price target
UBS analysts upgrade Bank of America (BAC) to Buy from Neutral and lift their price target to $53 from $43. The analysts ...
UBS Shares Rise as Exane Upgrades on Likely Buyback Increase
UBS Group AG shares rose the most in two months as analysts at BNP Paribas Exane recommended buying on expectations the Swiss ...
UBS boss warns against excessive banking regulation ahead of overhaul
Switzerland should not set rules for its banking sector that put it at a disadvantage, UBS CEO Sergio Ermotti was quoted as ...
AI stocks could continue their growth despite high valuations, says UBS
AI stocks and the "Magnificent Seven" were clear winners in 2024. But after a solid year of growth and high valuations, will that momentum continue in 2025? Perhaps, says UBS. In a note, UBS head of U ...
Series of factors will conspire to limit Hong Kong stock gains in 2025: UBS
The Swiss bank expects the city’s benchmark index to rise above 20,000 by year-end, implying a gain of 3.7 per cent from ...
Big 6 Stocks in S&P 500 Offer Cheaper Valuations Compared to Broader Index, UBS Says
UBS claims that although the larger market had a considerably lesser gain of 5.0%, the Big 6 saw profits rise of 38.9% in ...
UBS upgrades LPL Financial on more bullish environment
UBS upgraded LPL Financial (LPLA) to Buy from Neutral with a price target of $390, up from $280. The firm expects an acceleration of client ...
Bank of America upgraded to Buy from Neutral at UBS as stock ‘overlooked’
UBS upgraded Bank of America (BAC) to Buy from Neutral with a price target of $53, up from $43. UBS thinks Bank of America has largely been ...
Novo Nordisk upgraded at UBS as analysts call CagriSema sell-off "overdone"
Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...
Investing4h
UBS' survey results point to Nvidia, Microsoft and OpenAI as key AI winners
Investing.com -- Nvidia (NASDAQ: NVDA ), Microsoft (NASDAQ: MSFT ), and OpenAI are the key AI beneficiaries, UBS analysts said, citing results of its latest enterprise AI survey. The survey, which ...